Recommended Topic Related To:


"This week the U.S. Food and Drug Administration approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage).




The experience with overdose of SYLATRON is limited. Patients who were over dosed experienced the following adverse reactions: severe fatigue, headache, myalgia, neutropenia, and thrombocytopenia. The highest single dose administered was 14 mcg/kg.


SYLATRON is contraindicated in patients with:

  • A history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b
  • autoimmune hepatitis
  • hepatic decompensation (Child-Pugh score > 6 [class B and C])

Last reviewed on RxList: 9/10/2014
This monograph has been modified to include the generic and brand name in many instances.


Sylatron - User Reviews

Sylatron User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Sylatron sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options.